ArticleAntimicrobial agents and chemotherapy2016
Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 76 citations in OpenAlex.
- Carbon-based nanomaterials in biomedicine and technology.Frontiers in chemistry · 2026Review
- Synthesis of indano[60]fullerene thioketone and its application in organic solar cells.Beilstein journal of organic chemistry · 2024Article
- Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.International journal of molecular sciences · 2023Review
- In vitro and in silico studies of the antiviral activity of polyhydrated fullerenes against influenza A (H1N1) virus.Scientific reports · 2023Article
- Recent Advances in Carbon-Based Electrodes for Energy Storage and Conversion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Carbon-based nanomaterials against SARS-CoV-2: Therapeutic and diagnostic applications.OpenNano · 2023Article
- Progress in Antiviral Fullerene Research.Nanomaterials (Basel, Switzerland) · 2022Review
- Novel CMolecules (Basel, Switzerland) · 2022Article
- Development of antiviral carbon quantum dots that target the Japanese encephalitis virus envelope protein.The Journal of biological chemistry · 2022Article
- Progress in Diamanes and Diamanoids Nanosystems for Emerging Technologies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Fullerene Derivatives Prevent Packaging of Viral Genomic RNA into HIV-1 Particles by Binding Nucleocapsid Protein.Viruses · 2021Article
- Past and Current Progress in the Development of Antiviral/Antimicrobial Polymer Coating towards COVID-19 Prevention: A Review.Polymers · 2021Review
- Biomedical Applications of Carbon Nanomaterials: Fullerenes, Quantum Dots, Nanotubes, Nanofibers, and Graphene.Materials (Basel, Switzerland) · 2021Review
- Multivalent Tryptophan- and Tyrosine-Containing [60]Fullerene Hexa-Adducts as Dual HIV and Enterovirus A71 Entry Inhibitors.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19.Microbial pathogenesis · 2021Review
- Use of nanotechnology in combating coronavirus.3 Biotech · 2021Review
- Antiviral Nanomaterials for Designing Mixed Matrix Membranes.Membranes · 2021Review
- Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021Review
- Nano-based approaches in the development of antiviral agents and vaccines.Life sciences · 2021Review
- Pristine CNeurochemical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Three compounds (1, 2, and 3) previously reported to inhibit HIV-1 replication and/or in vitro activity of reverse transcriptase were studied, but only fullerene derivatives 1 and 2 showed strong antiviral activity on the replication of HIV-1 in human CD4(+) T cells. However, these compounds did not inhibit infection by single-round infection vesicular stomatitis virus glycoprotein G (VSV-G)-pseudotyped viruses, indicating no effect on the early steps of the viral life cycle. In contrast, analysis of single-round infection VSV-G-pseudotyped HIV-1 produced in the presence of compound 1 or 2 showed a complete lack of infectivity in human CD4(+) T cells, suggesting that the late stages of the HIV-1 life cycle were affected. Quantification of virion-associated viral RNA and p24 indicates that RNA packaging and viral production were unremarkable in these viruses. However, Gag and Gag-Pol processing was affected, as evidenced by immunoblot analysis with an anti-p24 antibody and the measurement of virion-associated reverse transcriptase activity, ratifying the effect of the fullerene derivatives on virion maturation of the HIV-1 life cycle. Surprisingly, fullerenes 1 and 2 did not inhibit HIV-1 protease in an in vitro assay at the doses that potently blocked viral infectivity, suggesting a protease-independent mechanism of action. Highlighting the potential therapeutic relevance of fullerene derivatives, these compounds block infection by HIV-1 resistant to protease and maturation inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.